Literature DB >> 10374674

Deficient DNA repair capacity: a predisposing factor and high risk predictive marker in familial colorectal cancer.

R Ankathil1, B Jyothish, J Madhavan, M K Nair.   

Abstract

Even though colorectal cancer tends to aggregate in families, there is paucity of information on the genetic determinism for familial colorectal cancer (FCRC) predisposition. Therefore, we investigated constitutional chromosome abnormalities and bleomycin induced chromosome sensitivity of 26 familial and 30 sporadic colorectal cancer (SCRC) patients, 60 unaffected family members (first/second degree relatives) and 30 normal healthy controls to determine whether these parameters could give any clues on genetic predisposing factors by which high risk members in CRC families could be identified. The test assay used bleomycin-induced chromatid breaks in short term microcultures of peripheral blood lymphocytes of the subjects. The CRC patients, the unaffected family members and the controls did not show any constitutional chromosomal abnormalities. However, with regard to bleomycin sensitivity, there was significant difference between the CRC patients, unaffected relatives and controls. The mean b/c values of 1.64+/-0.42 for the FCRC patients and 1.08+/-0.34 for the SCRC patients were significantly higher than the mean b/c values of 0.62+/-0.18 for the unaffected relatives and 0.52+/-0.12 for the controls (P<0.001). A noteworthy observation was that 6 unaffected members from 6 CRC families also showed bleomycin hypersensitivity, at the initiation of the study. Since they expressed mean b/c values greater than 1.0, which was as high a value as those of the patients, they were regularly followed up. Out of these 6 members, 2 developed CRC later. This clearly demonstrates that mutagen hypersensitivity among unaffected relatives in CRC families may be related to cancer predisposition. Hence, this cytogenetic assay could be utilised to identify the genetically high risk individuals in CRC families.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10374674

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  6 in total

1.  Mutagen sensitivity and p53 expression in colorectal cancer in China.

Authors:  L Shao; M Lai; Q Huang
Journal:  Postgrad Med J       Date:  2001-11       Impact factor: 2.401

2.  Chromosome instability and risk of squamous cell carcinomas of head and neck.

Authors:  Li-E Wang; Ping Xiong; Hui Zhao; Margaret R Spitz; Erich M Sturgis; Qingyi Wei
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

3.  Polymorphisms of the XRCC1, XRCC3, & XPD genes, and colorectal cancer risk: a case-control study in Taiwan.

Authors:  Chih-Ching Yeh; Fung-Chang Sung; Reiping Tang; Chung Rong Chang-Chieh; Ling-Ling Hsieh
Journal:  BMC Cancer       Date:  2005-01-28       Impact factor: 4.430

4.  Application of mutagen sensitivity assay in a glioma case-control study.

Authors:  Serap Erdal; Bridget J McCarthy; Natalia Gurule; Marianne Berwick; Emily Gonzales; Johanna Byrd; Kristina Flores; JoAnna Shimek; Dora Il'yasova; Francis Ali-Osman; Darell D Bigner; Faith G Davis; Alexis N Leyba; Kirsten A M White
Journal:  Toxicol Rep       Date:  2018-01-09

5.  ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study.

Authors:  Ming-Yii Huang; Wei-Yu Fang; Su-Chen Lee; Tian-Lu Cheng; Jaw-Yuan Wang; Shiu-Ru Lin
Journal:  BMC Cancer       Date:  2008-02-12       Impact factor: 4.430

6.  Exploring new potential role of DDB2 by host cell reactivation assay in human tumorigenic cells.

Authors:  Elisabetta Bassi; Paola Perucca; Isabella Guardamagna; Ennio Prosperi; Lucia A Stivala; Ornella Cazzalini
Journal:  BMC Cancer       Date:  2019-10-29       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.